Axsome Therapeutics Stock News

Two analysts boost their price targets on the company's stock.

The company announced that it was buying a therapy from Jazz Pharmaceuticals.

Axsome Therapeutics Inc (NASDAQ: AXSM) is trading higher Monday morning after the company announced it will acquire Sunosi from Jazz Therapeutics PLC (NASDAQ: JAZZ). Jazz will receive a total upfront

AXSM has a pivotal few months up ahead.

Potential to still achieve FDA approval of AXS-05 for patients with major depressive disorder; a response for CMC issues were submitted to the FDA and further review is ongoing.

These biotechs have promising near-term and long-term prospects.

Axsome Therapeutics (AXSM) reports a narrower-than-expected Q4 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat at the Cowen 42 nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 AM Eastern Time.

AXSM earnings call for the period ending December 31, 2021.

Investors appear to be convinced that AXS-05 will get a green light from the FDA soon.

Axsome Therapeutics <> stock rose following its Q4 results."2021 was a year of continued progress which has put us in a position to potentially launch two new…

Investors appear to be convinced that AXS-05 will get a green light from the FDA soon.

Company to host conference call today at 8:00 AM Eastern

Axsome Therapeutics, Inc.'s (AXSM) CEO Herriot Tabuteau on Q4 2021 Results - Earnings Call Transcript